MDFORLIVES FULL IN-DEPTH INSIGHT REPORT

Cancer Treatment Costs: When Financial Pressure Changes Care Decisions

A patient-centered analysis of cancer financial toxicity across five countries, examining when pressure peaks, which costs create the most strain, how affordability can change care, and what kinds of support patients say would help.

COST OF CARE → HOUSEHOLD PRESSURE → CARE DECISIONS → SUPPORT

99	5	68.7%	8979573
Survey records	Countries represented USA · UK · Italy · France · Germany	Completion rate	Survey ID

WHY THIS REPORT

Cancer costs can become a care issue before anyone calls them a financial issue.

For patients, affordability is rarely a single invoice. Treatment can bring medicines, hospital care, scans, deductibles, copays, non-covered services, travel, accommodation, caregiver needs, and time away from work at the same time. The result can be a financial problem that sits inside an already demanding treatment journey.

The practical tension is straightforward: a care plan may be clinically appropriate, but the patient still has to be able to reach appointments, obtain medicines, absorb time away from work, and meet the costs that insurance or public coverage does not fully remove. Financial strain can therefore influence treatment timing, medication use, follow-up, provider choice, and household decisions.

This report examines that tension from the patient's perspective. It follows the survey from direct treatment costs to payment pressure, from coping strategies to indirect costs, and from financial consequences to the kinds of support patients believe would make cancer care more manageable.

CANCER CARE & FINANCIAL CONTEXT

Financial toxicity combines the cost of care with the household's ability to absorb it.

The National Cancer Institute uses the term financial toxicity to describe financial problems related to the cost of medical care, including out-of-pocket costs, debt, work disruption, and stress. The World Health Organization places the same issue inside the broader idea of financial protection: people should be able to obtain needed care without health spending compromising their ability to meet basic needs.

That framing is important for a five-country survey because health systems differ. Insurance rules, public coverage, copays, medicine reimbursement, social benefits, and financial-assistance pathways are not the same in the USA, UK, Italy, France, and Germany. The survey should therefore be read as a picture of the pressures reported by this respondent group, not as a comparison of national health systems.

Methodology: The source report contains 99 survey records with a 68.7% completion rate across the USA, UK, Italy, France, and Germany. Reader-facing quantitative items use the question-level bases recorded in the source report, ranging from 70 to 73 responses. The open-ended item contains 20 visible responses. Internal tracking, bad-ID, stored-text, after-survey, and honeypot fields are excluded from the analysis. No qualitative percentages were created.

EXECUTIVE SUMMARY

Six signals that show how cancer costs move from bills into everyday care decisions.

INSIGHT 01

54.3% - Income loss is the biggest indirect burden

Lost income or employment is selected more often than travel, caregiving, or household costs, showing why affordability cannot be understood from medical bills alone.

INSIGHT 02

51.4% - Pressure peaks during active treatment

The period of most intensive care is also when many households face the strongest financial pressure.

INSIGHT 03

47.9% - Cancer medicines lead direct cost burden

Medicines are selected ahead of surgery or hospital care, tests and scans, and travel or caregiving as the largest cancer-care expense.

INSIGHT 04

40.0% - Financial stress has an emotional consequence

Emotional stress about finances is the most selected financial consequence, slightly ahead of depleted savings or increased debt.

INSIGHT 05

37.1% - Patients want direct financial assistance

Patient financial assistance is the support most often selected as likely to improve the cancer-care experience.

INSIGHT 06

38.6% - Reimbursement is the top affordability change

Better insurance reimbursement leads when patients are asked which system change would make cancer care more affordable.

01 CARE JOURNEY

Most respondents are already living with cancer treatment or follow-up

78.1% of respondents to the care-status item say they are currently receiving cancer treatment or follow-up care.

CONTEXT

Financial pressure looks different depending on where a person is in the cancer journey. Someone planning treatment may be facing new estimates and insurance questions, while someone already in active care may be managing recurring medicine, visit, travel, and income costs.

WHAT THE DATA SHOWS

78.1% say they are currently receiving cancer treatment or follow-up care, while 21.9% say they are currently seeking or planning cancer treatment.

THE INSIGHT

The survey is weighted toward people who have already encountered the practical realities of cancer care. Their answers therefore reflect not only expectations about cost but lived experience with treatment, follow-up, work, insurance, transport, and household trade-offs.

WHY IT MATTERS

Support needs to fit the stage of care. People planning treatment may benefit from early cost and coverage conversations, while those already in care may need help with recurring out-of-pocket costs, transport, income disruption, payment plans, or assistance programs.



02 DIRECT COST BURDEN

Cancer medicines create the greatest direct financial burden

47.9% identify cancer medicines as the cancer-care expense creating the greatest financial burden.

CONTEXT

A cancer treatment plan can include several cost categories at once, but patients do not necessarily experience each category with the same intensity. Medicines can bring repeated costs over time, while surgery, hospital care, tests, scans, travel, and caregiving can create different payment patterns.

WHAT THE DATA SHOWS

Cancer medicines lead at 47.9%, followed by surgery or hospital care at 20.5%, travel and caregiving at 16.4%, and tests and diagnostic scans at 15.1%.

THE INSIGHT

The leading role of medicines helps explain why affordability can remain a recurring concern rather than a one-time shock. A hospital bill may be concentrated around an episode of care; medicine costs can recur through active treatment and beyond, depending on the regimen and coverage structure.

WHY IT MATTERS

Medication affordability should be discussed before cost pressure becomes a reason to alter how a medicine is taken. The open responses include an example of a patient who could not afford cancer medication until free samples were provided and another who described taking a reduced dose because chemotherapy medicines were too expensive. These are patient reports, not recommended coping strategies, and they underline why cost concerns need to be surfaced early with the care team.



03 TIMING OF PRESSURE

Active treatment is the point where financial pressure most often peaks

51.4% say cancer-related financial pressure is highest during active treatment.

CONTEXT

Financial burden is not static. Different phases of cancer care bring different combinations of tests, visits, medicines, hospital care, transportation, caregiving, and work disruption. Knowing when pressure peaks can help identify when navigation and assistance are most likely to be useful.

WHAT THE DATA SHOWS

Active treatment leads at 51.4%. Long-term or maintenance care follows at 27.8%, diagnosis and initial testing at 16.7%, and the period after treatment ends at 4.2%.

THE INSIGHT

Active treatment can concentrate multiple pressures in the same weeks or months. A patient may face medicine costs, repeated appointments, travel, time away from work, caregiver needs, and recurring insurance cost-sharing at the same time. This helps explain why the financial problem can feel larger than any single line item.

WHY IT MATTERS

If financial screening, benefits checks, transportation help, or assistance referrals happen only after treatment is already underway, the patient may already have used savings or changed household spending. Earlier support can shift the conversation from crisis response to planning.



04 PAYMENT PRESSURE

Out-of-pocket exposure remains the biggest payment challenge

33.3% identify high out-of-pocket costs as the payment challenge creating the greatest financial pressure.

CONTEXT

Having insurance or public coverage does not necessarily mean a patient experiences cancer care as affordable. What matters to the household is the amount it still has to pay directly, how often those payments recur, and whether the costs arrive alongside income loss or other obligations.

WHAT THE DATA SHOWS

High out-of-pocket costs lead at 33.3%, followed by insurance deductibles or copays at 29.2%, non-covered treatments or medicines at 27.8%, and unexpected medical bills at 9.7%.

THE INSIGHT

The three leading categories are closely grouped, suggesting that the burden is spread across several forms of patient payment rather than dominated by one mechanism. The exact meaning varies by country, but the common thread is the gap between the total cost of care and what the household can safely absorb.

WHY IT MATTERS

A useful affordability conversation should ask what the patient expects to pay, when payment is due, whether coverage resets or authorization is pending, and which costs sit outside formal benefits. One open response specifically describes the beginning of the year as difficult when deductible and out-of-pocket limits reset.



05 CARE CHANGES

Financial pressure changes treatment or follow-up for a meaningful share of patients

23.6% report delayed cancer treatment and another 23.6% report missed medicines or follow-ups because of cancer-related cost pressure.

CONTEXT

Financial toxicity becomes clinically important when affordability starts shaping whether a person can follow the intended care plan. The National Cancer Institute notes that patients facing financial toxicity may sometimes avoid or change medication use because of cost.

WHAT THE DATA SHOWS

Delayed cancer treatment and missed medicines or follow-ups are each selected by 23.6%. Another 20.8% say they changed treatment or provider. 31.9% report no major treatment change.

THE INSIGHT

The data do not say that every financially stressed patient changes care, and nearly one-third explicitly report no major treatment change. But the combined picture shows several points where affordability can enter the treatment pathway: starting on time, continuing medicines, returning for follow-up, and staying with the original provider or plan.

WHY IT MATTERS

Patients should not have to quietly improvise around cost. If affordability is threatening a medicine, appointment, or treatment step, the cancer care team may be able to connect the patient with a social worker, financial navigator, insurer, public benefit, charity, manufacturer assistance program, or other locally available support.



06 COPING STRATEGIES

Savings and family support are the first line of financial coping

40.8% say they use savings or family support when cancer-care costs become unaffordable.

CONTEXT

When care costs exceed what a household can comfortably pay from current income, families have to find another source of money or reduce something else. The coping strategy itself can reveal how far the financial burden has moved beyond the healthcare bill.

WHAT THE DATA SHOWS

Using savings or family support leads at 40.8%. Seeking financial assistance follows at 32.4%, borrowing money or using credit at 19.7%, and reducing or delaying other spending at 7.0%.

THE INSIGHT

The coping ladder starts with household resources and social networks before moving to debt. That can protect treatment in the short term while leaving a longer financial after-effect. Open responses describe parents helping with payment, family members raising money, moving in with relatives, and borrowing for accommodation.

WHY IT MATTERS

Financial support is not only about preventing a missed bill. It can reduce the need to draw down savings, depend heavily on relatives, or add debt during treatment. Early referral to available support may preserve more options for the household.



07 INDIRECT COSTS

Lost income makes the burden of cancer bigger than the price of healthcare

54.3% say lost income or employment is the indirect cost affecting their household most.

CONTEXT

Cancer can create a two-sided financial problem: expenses rise at the same time that the ability to earn can fall. The National Cancer Institute identifies work disruption and lower income as important contributors to financial toxicity, while the American Cancer Society also highlights travel and other non-medical expenses.

WHAT THE DATA SHOWS

Lost income or employment leads at 54.3%. Travel and accommodation follows at 18.6%, caregiver expenses at 15.7%, and household or childcare costs at 11.4%.

THE INSIGHT

The largest indirect burden is not a charge from the hospital or pharmacy. It is missing income. This can make even a stable treatment cost harder to sustain because the denominator has changed: the household has less money available to absorb every other expense.

WHY IT MATTERS

Support plans that focus only on medical bills can miss transport, accommodation, work leave, caregiver time, or employment instability. One open response describes family and friends taking time off work to provide transportation; another describes borrowing heavily for an unexpected test in another town.



08 FINANCIAL CONSEQUENCES

The emotional cost of financial pressure is as visible as the balance-sheet cost

40.0% identify emotional stress about finances as the financial consequence affecting them most.

CONTEXT

Financial toxicity is not only measured in debt. Worry about bills, insurance, work, and future expenses can become a parallel stressor during cancer treatment. That psychological burden can exist even before a household reaches a formal financial crisis.

WHAT THE DATA SHOWS

Emotional stress about finances leads at 40.0%, closely followed by depleted savings or increased debt at 37.1%. Reduced household spending is selected by 21.4%, while reduced spending on other healthcare is selected by 1.4%.

THE INSIGHT

The leading two consequences sit in different domains: one emotional, one material. Together they show why cancer-related financial burden can be experienced as both a household-finance problem and a source of distress.

WHY IT MATTERS

Financial distress can be easier to miss than a visible unpaid bill. A structured question about cost worry, work, debt, or transport can give patients permission to raise a problem that otherwise stays outside the clinical conversation.



09 WHAT WOULD HELP

Patients prioritize assistance and coverage that reduce the amount they must absorb

37.1% say patient financial assistance would improve their cancer-care experience most, and 38.6% say better insurance reimbursement would make cancer care more affordable.

CONTEXT

Patients can value information, but affordability ultimately depends on whether the amount due is manageable. The survey therefore asks two slightly different questions: what support would improve the care experience, and what system change would make care more affordable.

WHAT THE DATA SHOWS

For care experience, patient financial assistance leads at 37.1%, followed by broader insurance coverage at 34.3%, lower treatment costs at 24.3%, and upfront cost estimates at 4.3%. For affordability, better insurance reimbursement leads at 38.6%, followed by lower medicine and treatment costs at 30.0%, expanded financial assistance at 28.6%, and greater cost transparency at 2.9%.

THE INSIGHT

Both questions point toward mechanisms that change financial exposure rather than only explaining it. Transparency matters for planning, but respondents more often choose assistance, coverage, reimbursement, or lower treatment costs when asked for the single biggest improvement.

WHY IT MATTERS

Patients need both information and a path to action. Cost estimates are most useful when they are paired with someone who can explain coverage, identify assistance, discuss payment options, and connect patients with transport, social benefits, or other practical resources available in the local system.



OPEN RESPONSE LENS

In patients' own words, financial pressure appears as a series of practical compromises.

Respondents were asked to describe a time when cancer costs affected a treatment or family decision, explain what happened, how they coped, and what support would have helped most. Twenty visible responses were reviewed qualitatively. They include comments in English, French, Italian, and German, and they do not all point in the same direction.

Medicine affordability can reach the treatment itself

Several responses focus directly on the price of cancer medicines. One person describes being unable to afford medication after being out of work and receiving free samples from the oncology team. Another reports reducing a chemotherapy dose because medicine costs were too high. These accounts show why cost concerns need a clinical response rather than private improvisation by the patient.

Insurance and annual cost-sharing resets create recurring pressure

One response describes the beginning of the year as particularly difficult when deductibles and out-of-pocket limits reset, followed by time spent comparing options, talking to insurance, arranging payment plans, and timing treatment around what could be paid.

Family, social workers, and case management can become part of the care pathway

Respondents mention parents helping with payment, family members raising money, working with case management, and receiving help from a social worker at a cancer center. These are not peripheral details: they are examples of how navigation and social support can protect continuity when affordability is strained.

Travel, work, and housing create financial pressure outside the clinic

Responses describe relatives taking time off work to provide transportation, borrowing for accommodation after an unexpected test in another town, and moving into a crowded family home while financial assistance was available only temporarily.

Some patients report that public coverage cushions the burden

A small number of responses say the problem did not occur or note that the national health system covered much of the care. These comments are important because they show that financial toxicity is shaped by local coverage and household circumstances, not by cancer alone.

Emotional strain often sits beside the financial problem

One response simply asks for financial and emotional support; another describes the experience as very exhausting. The structured data echo this, with emotional stress about finances emerging as the most selected financial consequence.

What the qualitative responses add: The survey percentages identify where pressure is concentrated, while the open responses show how that pressure is lived: medicine affordability, insurance administration, work disruption, transport, family dependence, borrowing, temporary assistance, and uncertainty about the next expense. No qualitative percentages were created, and responses reporting no major financial impact were retained as contrasting perspectives.

PEOPLE ALSO ASK · TOPIC FAQ

Frequently asked questions about cancer treatment costs.

What is financial toxicity in cancer care?

Financial toxicity is the financial strain caused by the costs of cancer and its treatment. It can include medical bills, medicines, deductibles or copays, travel, lost income, debt, and the stress created by trying to afford care.

Why can cancer treatment be expensive even when someone has insurance?

Insurance may not cover every medicine, service, facility, or related cost. Deductibles, copays, coinsurance, non-covered treatments, travel, and time away from work can still create a substantial household burden.

What costs besides treatment can affect people with cancer?

Indirect costs can include lost income, unpaid leave, transportation, accommodation, childcare, caregiver expenses, and other household costs that rise while a person is receiving or travelling for care.

Can cancer treatment costs affect appointments or medicines?

Yes. Financial strain can sometimes lead people to delay care, miss appointments, change treatment plans, or alter how they use medicines. Patients should tell their cancer care team if cost is making any part of treatment difficult.

What is cancer financial assistance?

Cancer financial assistance can include hospital or charity programs, social-work support, insurance navigation, manufacturer assistance, government benefits, transportation help, or other locally available resources. Eligibility and availability vary by country and health system.

When should patients ask about the expected cost of cancer care?

It is reasonable to ask as early as possible and again when treatment changes. Questions can cover expected out-of-pocket costs, insurance authorization, medicine coverage, travel, time away from work, and who can help with financial or practical support.

PATIENT ACCESS LENS

Four points where financial support can become part of cancer care rather than an afterthought.

The survey suggests that affordability support is most useful when it addresses both the medical cost and the practical conditions that determine whether a patient can continue care.

Early financial-risk conversation

Focus: Ask about expected out-of-pocket costs, work disruption, travel, insurance or public coverage, and whether any part of the plan already feels unaffordable before treatment starts.

Coverage and reimbursement navigation

Focus: Help patients understand authorization, reimbursement, deductibles, copays, non-covered services, medicine benefits, and locally available public or insurer support.

Financial and practical assistance

Focus: Connect patients with social workers, financial navigators, charities, manufacturer programs, transport support, payment plans, or other resources that fit the local health system.

Watch for cost-related care changes

Focus: Revisit affordability when treatment changes, because missed medicines, delayed care, provider changes, or reduced follow-up can be signals that the financial plan is no longer sustainable.

CLOSING PERSPECTIVE

Cancer care becomes harder to sustain when treatment costs rise at the same time household capacity falls.

The survey describes financial toxicity as a chain rather than a single event. Direct expenses create pressure, active treatment concentrates that pressure, lost income reduces the household's ability to absorb it, and patients then turn to savings, family support, assistance, credit, or changes in care. The financial problem and the treatment journey become connected.

The first part of the chain is direct cost. Cancer medicines are the expense most often identified as creating the greatest burden. Payment pressure then appears through high out-of-pocket costs, deductibles or copays, and non-covered treatments or medicines. These categories differ across countries and insurance systems, but they share one patient-level reality: some portion of care remains financially exposed.

The second part is timing. More than half of respondents to the timing item say pressure peaks during active treatment. That is when medical expenses can combine with repeated visits, travel, time away from work, caregiver needs, and the administrative effort of navigating insurance or assistance. Waiting for a financial problem to become visible may therefore mean waiting until the most difficult part of the journey.

The third part is income. Lost income or employment is the largest indirect cost in the survey. This matters because affordability depends on both sides of the household equation: what must be paid and what money is still coming in. A patient can face the same treatment bill and experience it very differently after weeks away from work or a change in employment.

The fourth part is treatment continuity. Cost-related delayed treatment, missed medicines or follow-ups, and treatment or provider changes all appear in the survey. These findings should not be read as proof that cost caused every clinical outcome, but they do show where financial pressure can enter the care pathway. The safest response is to make affordability discussable before patients feel forced to solve it alone.

The final part is support. Patients most often choose financial assistance and broader coverage as the support that would improve their care experience, while better insurance reimbursement leads the affordability question. Open responses add the human detail: social workers, family help, payment plans, free medicine samples, transport grants, public health coverage, and case management can all change what is possible. The right mix will vary by health system, but the principle is consistent: patients need a clear route from financial concern to practical help.

1 · Treat affordability as part of care planning

Ask about cost before treatment starts and whenever the plan changes, rather than waiting for missed care or debt to reveal the problem.

2 · Look beyond the medical bill

Include work, transport, accommodation, caregiving, childcare, and household expenses when discussing whether treatment is financially sustainable.

3 · Pay attention during active treatment

This is where financial pressure peaks most often in the survey, making it a logical point for proactive check-ins and navigation.

4 · Connect patients to a real person who can help

Social workers, financial navigators, case managers, insurers, public-benefit advisers, and assistance programs can turn a cost conversation into an action plan.

5 · Watch for cost-related changes in care

Delayed treatment, missed medicines, missed follow-up, or provider changes can be signals that the financial plan needs to be revisited urgently.

6 · Adapt support to the local health system

Coverage, reimbursement, assistance programs, and public benefits differ by country, so support should be specific to what is actually available where the patient receives care.

REFERENCES AND DATA SOURCE

Sources used for this report

1. **MDForLives internal survey report.** All SGID report for 8979573, Project: Engagement Campaign | Sep-Cancer patients Insight Survey. 99 survey records, 68.7% completion rate, across USA, UK, Italy, France, and Germany. Reader-facing quantitative items use the question-level bases recorded in the source report. Twenty visible open-ended responses were reviewed qualitatively. No qualitative percentages were created.
2. **National Cancer Institute.** Financial Toxicity (Financial Distress) and Cancer Treatment - Patient Version. Defines financial toxicity and summarizes how cancer costs, work disruption, insurance, debt, medication use, and quality of life can interact.
3. **World Health Organization.** Financial protection. Global context on out-of-pocket health spending, access to needed care, and protection from healthcare payments that compromise basic needs.
4. **American Cancer Society.** Managing the Cost of Cancer Care. Patient-oriented context on treatment costs, insurance, medicines, travel, out-of-pocket expenses, and loss of income.
5. **Samaha NL, et al.** Screening for Financial Toxicity Among Patients With Cancer: A Systematic Review. Journal of the American College of Radiology, 2024. Reviews approaches used to identify and assess financial toxicity among patients with cancer.